Results 161 to 170 of about 1,472,301 (348)
Sorafenib in advanced clear-cell renal-cell carcinoma.
New England Journal of Medicine, 2007 B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Négrier, C. Chevreau, E. Solska, A. Desai, F. Rolland, T. Demkow, Thomas E. Hutson, M. Gore, S. Freeman, B. Schwartz, M. Shan, R. Simantov, R. Bukowski +18 moresemanticscholar +1 more sourceFully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors
Advanced Science, EarlyView.This study reports the development of a fully humanized bispecific T cell engager targeting IL13RA2, a tumor‐associated antigen enriched in glioblastoma. This off‐the‐shelf immunotherapy drives potent, antigen‐dependent T cell activation and tumor killing, and prolongs survival in experimental GBM and other solid tumors models without detectable off ...Joseph T. Duffy, Angela Martin‐Regalado, Benedikt E. Haupt, Jacob R. Pogue, Aditi Thakur, Manuel Fierro Cota, Markella Zannikou, Sol Misener, Vera P. Krymskaya, Kathleen McCortney, Jason Miska, Craig Horbinski, Dmitri Simberg, Maciej S. Lesniak, Charles D. James, Roger Stupp, Irina V. Balyasnikova +16 morewiley +1 more sourceMetastatic Renal Cell Carcinoma (RCC) [PDF]
, 1991 A. V. Bono, C. Stief, D. E. Johnson, D. G. Skinner, D. H. Garfield, D. J. Fairlamb, D. W. McNichols, E. Allhoff, G. L. Rohdenburg, G. T. Hultquist, H. C. Bumpus Jr., H. E. Stephenson Jr., H. J. G. Bloom, H. J. G. Bloom, H. J. G. Bloom, H. Takatera, I. Satake, J. B. Kernion De, J. B. Kernion De, J. C. Donaldson, J. E. Montie, K. Goldenberg, L. R. Kavoussi, M. M. Mims, R. C. Klugo, R. G. Middleton, R. M. Snow, R. Schlick, S. E. Katz, S. Liedke, S. Z. Freed, T. C. Everson, U. Jonas, W. de Riese, Z. Wajsman +34 morecore +1 more sourceNanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives
Advanced Science, EarlyView.This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon +19 morewiley +1 more sourceS100A14 in Tumor‐Derived EVs Targets PIAS3 to Reprogram Astrocytes and Induce Immunosuppressive Microenvironment Promoting Brain Metastasis and Germacrone Reversal Effect
Advanced Science, EarlyView.This study identifies S100A14 in tumor‐derived exosomes as a key driver of brain metastasis. S100A14 targets PIAS3 in astrocytes, activating STAT3 signaling and promoting immunosuppressive MDSCs recruitment via chemokine secretion. Germacrone, a natural compound, binds S100A14 to disrupt this axis, effectively inhibiting brain metastasis with low ...Qian Feng, Xia Yang, Lin An, Xue‐Yu Wang, Ming‐Rui Wang, Zhuo‐Hong Cai, Cai‐Jun Xie, Li‐Jun Qiao, You‐Bi Shen, Xi‐Min Liang, Rong Zhang, Cai‐Yan Wang, Zhong‐Qiu Liu, Rong‐Rong Zhang +13 morewiley +1 more sourceTumor‐Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T‐Cell Infiltration and Limiting Myeloid Cell‐Mediated Immunosuppression
Advanced Science, EarlyView.ARHGEF3 is broadly downregulated across human cancers and correlates with patient prognosis. Tumor‐intrinsic ARHGEF3 activates the RHOA–ROCK–PTEN cascade to inhibit AKT signaling, thereby promoting chemokine‐driven T‐cell infiltration and relieving lipid‐mediated myeloid immunosuppression.Yue Li, Lan Wang, Zihao Zhang, Chunmei Qian, Ning Li, Wei Huang, Qian Ba, Xiaojian Liu, Mayu Sun +8 morewiley +1 more sourceTemsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
New England Journal of Medicine, 2007 G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Starosławska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovačević, V. Lesovoy, I. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore, R. Motzer +18 moresemanticscholar +1 more sourceIntegrating Radiomics and Computational Pathology to Predict Early Recurrence of Pancreatic Ductal Adenocarcinoma and Uncover Its Biological Basis in Tumor Microenvironment
Advanced Science, EarlyView.Accurate prediction of early recurrence in pancreatic ductal adenocarcinoma is vital for optimizing treatment. A novel, integrated radiomics‐pathology machine learning model successfully forecasts recurrence risks by analyzing preoperative CT images and computational pathology.Sihang Cheng, Fuze Cong, Shenbo Zhang, Rui Lv, Wenjia Zhang, Xinyi Ke, Juncheng Wu, Zhonghe Zhao, Kui Zhao, Di Dong, Ruofan Zhang, Zhengyu Jin, Max Seidensticker, Zhiwei Wang, Huanwen Wu, Xianlin Han, Nan Hong, Huadan Xue +17 morewiley +1 more sourceBioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell Carcinoma
Advanced Science, EarlyView.This study reported renal‐clearable bio‐orthogonal near‐infrared fluorogenic probes (BGRs) that specifically imaging and urinalysis of granzyme B for dynamic evaluation of RCC immunotherapy. BGRs not only differentiate immunotherapeutic responses in orthotopic RCC mice, but also enable sensitive optical urinalysis of granzyme B in clinical specimens ...Xingyue Yang, Baoshuai Liang, Liangmin Fu, Weiliang Deng, Yuyan Jiang, Weiping Xu, Jinwei Chen, Ya Zhou, Ke Wu, Jiaguo Huang +9 morewiley +1 more source